Prospective, 6 Month, Open Label, Conversion Study From MMF [mycophenolate mofetil] to PRMYFORTIC [mycophenolate-sodium] Evaluating the Severity of GI [gastrointestinal] Symptoms and MPA [mycophenolic acid] Metabolite as a Surrogate Marker of MYFORTIC [mycophenolic acid].

Trial Profile

Prospective, 6 Month, Open Label, Conversion Study From MMF [mycophenolate mofetil] to PRMYFORTIC [mycophenolate-sodium] Evaluating the Severity of GI [gastrointestinal] Symptoms and MPA [mycophenolic acid] Metabolite as a Surrogate Marker of MYFORTIC [mycophenolic acid].

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2014

At a glance

  • Drugs Mycophenolate sodium (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jul 2013 Planned End Date changed from 1 Dec 2012 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 27 Jul 2011 Planned end date changed from 1 Aug 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top